Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced an update to the ArteraAI Prostate Test, enabling clinicians to make more informed decisions about active surveillance when delivering care to prostate cancer patients.
The ArteraAI Prostate Test, powered by Artera’s MMAI platform, is the first of its kind to both estimate how a patient’s cancer may progress and predict therapy benefit in localized prostate cancer, the company said.
According to the company, the prognostic performance of the test has now been validated in a diverse cohort of patients, including those who have undergone active surveillance, radiation therapy, or had a radical prostatectomy. The prognostic risk result reflects the patient’s prognosis regardless of the treatment path chosen.
Recently, PathNet, a digital pathology lab offering innovative solutions and advanced diagnostic technology, integrated the ArteraAI Prostate Test as a part of their test offerings. This partnership extends the distribution of the ArteraAI Prostate Test to PathNet’s extensive network of 200+ clinics across 27 states. This collaboration empowers clinicians with additional insights through comprehensive test reports, enhancing decision making and patient care.
The PathNet partnership is timely, since Artera’s updated test report now provides additional information to facilitate informed discussions around active surveillance with patients. This enhancement is crucial in supporting cancer management decisions for many of PathNet’s clients, as well as the broader prostate cancer community.
Clinicians and patients consider several factors when determining the suitability of active surveillance for prostate cancer. The updated ArteraAI Prostate Test report now provides information on a patient’s relative risk of their cancer showing more aggressive features, helping to guide decisions on the use of active surveillance. By showing where a patient’s risk falls relative to those managed on active surveillance, the report can offer clearer guidance on whether active surveillance may be considered appropriate.
Artera plans to continue further validation of its MMAI platform and inclusion of insights to the test report in order to provide greater confidence in treatment decision-making to those facing cancer. The addition of specific guidance regarding active surveillance decisions represents the next step in Artera’s ongoing commitment to continually improving the clinical utility of its tests for patients with cancer.
